Julie Zhen Qin Wu

Array ( [id] => 17480507 [patent_doc_number] => 20220088011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => THERAPEUTIC AGENT FOR A TUMOR COMPRISING AN IDO INHIBITOR ADMINISTERED IN COMBINATION WITH AN ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/519990 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830146 [patent_doc_number] => 20220267450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE [patent_app_type] => utility [patent_app_number] => 17/501362 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734999 [patent_doc_number] => 20220220458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy [patent_app_type] => utility [patent_app_number] => 17/465203 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511391 [patent_doc_number] => 20230227538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => SARS-COV2 NEUTRALIZING SINGLE DOMAIN ANTIBODY CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 17/998605 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -96 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998605 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20849701 [patent_doc_number] => 12686725 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-21 [patent_title] => Anti-DLL3 antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 17/997907 [patent_app_country] => US [patent_app_date] => 2021-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 25883 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 255 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675095 [patent_doc_number] => 20230312671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => GRP78 TARGETED ADOPTIVE CELL THERAPY [patent_app_type] => utility [patent_app_number] => 17/919728 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34713 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20548785 [patent_doc_number] => 12559565 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-24 [patent_title] => Antibodies binding CTLA4 and uses thereof [patent_app_type] => utility [patent_app_number] => 17/907442 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 23 [patent_no_of_words] => 14946 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18366261 [patent_doc_number] => 20230147852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => Engineered Antibodies That Bind LAG3 [patent_app_type] => utility [patent_app_number] => 17/915437 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23552 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17915437 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16991877 [patent_doc_number] => 20210230297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => Antibodies Useful for Detection of Human Carcinoma Antigen [patent_app_type] => utility [patent_app_number] => 17/208977 [patent_app_country] => US [patent_app_date] => 2021-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17208977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18365002 [patent_doc_number] => 20230146593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => METHOD FOR TREATMENT AND PROPHYLAXIS OF CRS IN PATIENTS COMPRISING A COMBINATION OF BISPECIFIC ANTIBODIES BINDING TO CDS X CANCER CELL AND TNF ALPHA OR IL-6 INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/910698 [patent_app_country] => US [patent_app_date] => 2021-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 182106 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20701423 [patent_doc_number] => 12624123 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-12 [patent_title] => Compositions and methods for reducing off-target toxicity of antibody drug conjugates [patent_app_type] => utility [patent_app_number] => 17/782549 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 63 [patent_no_of_words] => 20116 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170889 [patent_doc_number] => 20240156863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => SEQUENTIAL ANTI-CD19 THERAPY [patent_app_type] => utility [patent_app_number] => 17/773117 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17096957 [patent_doc_number] => 20210284748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => ANTIBODY CONSTRUCTS FOR CD70 AND CD3 [patent_app_type] => utility [patent_app_number] => 17/084088 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55448 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17760054 [patent_doc_number] => 20220233666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => CANCER VACCINE [patent_app_type] => utility [patent_app_number] => 17/264469 [patent_app_country] => US [patent_app_date] => 2020-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29094 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17264469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056318 [patent_doc_number] => 20220387404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => TREATMENT OF CANCER USING A COMBINATION COMPRISING MULTI-TYROSINE KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/642125 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11493 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754053 [patent_doc_number] => 20230357425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => ANTI-CD73 ANTIBODY AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/636848 [patent_app_country] => US [patent_app_date] => 2020-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35548 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17636848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828487 [patent_doc_number] => 20220265791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => TARGET PEPTIDES FOR CANCER THERAPY AND DIAGNOSTICS [patent_app_type] => utility [patent_app_number] => 17/629311 [patent_app_country] => US [patent_app_date] => 2020-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851929 [patent_doc_number] => 20220281971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => Functional Binders Synthesized and Secreted by Immune Cells [patent_app_type] => utility [patent_app_number] => 17/597582 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17597582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020651 [patent_doc_number] => 20220372150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => ANTI-PD-L1 SINGLE-DOMAIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/637019 [patent_app_country] => US [patent_app_date] => 2020-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17637019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020959 [patent_doc_number] => 20220372458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => SIALIDASE-PD-L1-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/624116 [patent_app_country] => US [patent_app_date] => 2020-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44626 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -64 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624116 [rel_patent_id] =>[rel_patent_doc_number] =>)